An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.

Study Overview

• Status: Completed
• Conditions: Colitis, Ulcerative
• Intervention / Treatment: Biological: Placebo; Biological: Golimumab 100 mg; Biological: Golimumab 50 mg; Biological: Golimumab 200 mg

Detailed Description

This was a Phase 3, multicenter (conducted in more than one center), placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), double-blind (neither the Physician nor the participant know about the study medication), parallel-group (a medical research study comparing the response in 2 or more groups of participants receiving different interventions), randomized-withdrawal study. Participants who were in clinical response to golimumab at Week 6 in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) will be randomly assigned in a 1:1:1 ratio at Week 0 of this study to receive 1 of the following maintenance treatment regimens administered subcutaneously every 4 weeks through Week 52: placebo, golimumab 50 mg, or golimumab 100 mg. Participants who were in clinical response to placebo and participants who were not in clinical response to golimumab or placebo at Week 6 in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) will not be randomly assigned but will be eligible to be enrolled in the study (i.e., the nonrandomized group) and received the following treatment regimens: placebo, golimumab 100 mg and golimumab 100 mg. Dose adjustment will be done for participants who were in clinical response to golimumab or placebo during induction studies C0524T16 (NCT00488774) or C0524T17 (NCT00487539) but lose clinical response during maintenance study C0524T18 (NCT00488631). On completing this study, participant will have the opportunity to continue to receive study medication in a study extension that will last up to approximately 3 years. Efficacy will be primarily evaluated by assessing the clinical response using Mayo Score. Participants' safety will be monitored throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 1228
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia
  • Bankstown, Australia
  • Box Hill, Australia
  • Brisbane, Australia
  • Cairns, Australia
  • Fitzroy, Australia
  • Fremantle, Australia
  • Herston, Australia
  • Launceston, Australia
  • Malvern, Australia
  • Parkville, Australia
  • Prahran, Australia
  • Westmead, Australia
• Austria
  • Innsbruck, Austria
  • Wien N/A, Austria
• Belgium
  • Bonheiden, Belgium
  • Brussel, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Roeselare, Belgium
• Bulgaria
  • Bulgaria, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
• Canada
  • Quebec, Canada
  • Toronto, Canada
  • Windsor, Canada
  • Alberta
    • Calgary, Alberta, Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
    • Victoria, British Columbia, Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada
  • Ontario
    • Barrie, Ontario, Canada
    • Chatham, Ontario, Canada
    • Hamilton, Ontario, Canada
    • Kingston, Ontario, Canada
    • London, Ontario, Canada
    • Vaughan, Ontario, Canada
  • Quebec
    • Montreal, Quebec, Canada
  • Saskatchewan
    • Saskatoon, Saskatchewan, Canada
• Czech Republic
  • Hradec Kralove, Czech Republic
  • Litomerice, Czech Republic
  • Ostrava, Czech Republic
  • Èeské Budìjovice 1, Czech Republic
• Denmark
  • Aalborg, Denmark
  • Aarhus C., Denmark
  • Hvidovre, Denmark
  • Odense C, Denmark
• France
  • Amiens Cedex 1 80, France
  • Bordeaux 33, France
  • Clichy, France
  • Lille Cedex, France
  • Marseille Cedex 13, France
  • Nice Cedex 3, France
  • Paris, France
  • Rouen, France
• Germany
  • Aachen, Germany
  • Berlin, Germany
  • Berlin Be, Germany
  • Bochum, Germany
  • Frankfurt, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Heidelberg, Germany
  • Herne, Germany
  • Jena, Germany
  • Kiel, Germany
  • Magdeburg, Germany
  • Minden, Germany
  • Muenchen, Germany
  • München, Germany
  • Münster, Germany
  • Neustadt, Germany
  • Stade, Germany
• Hungary
  • Balatonfured, Hungary
  • Budapest, Hungary
  • Budapest N/A, Hungary
  • Debrecen, Hungary
  • Dunaujvaros, Hungary
  • Gyula, Hungary
  • Gyulai Ut 18, Hungary
  • Gyõr, Hungary
  • Miskolc, Hungary
  • Mosonmagyarovar, Hungary
  • Pécs, Hungary
  • Siofok, Hungary
  • Sopron, Hungary
  • Szeged, Hungary
  • Szekesfehervar, Hungary
  • Szekszard, Hungary
  • Szombathely, Hungary
  • Veszprém, Hungary
  • Zalaegerszeg, Hungary
• India
  • Bangalore, India
  • Chennai, India
  • Hyderabad, India
  • Hyderabad Andh Prad, India
  • Jaipur, India
  • Karnad, India
  • Lucknow Gpo, India
  • Ludhiana, India
  • New Delhi, India
  • Pune, India
  • Vishakapatanam, India
• Israel
  • Afula, Israel
  • Beer Sheva, Israel
  • Beer Yaakov, Israel
  • Haifa, Israel
  • Hedera, Israel
  • Jerusalem, Israel
  • Kfar Sava, Israel
  • Kiryat Bialik, Israel
  • Nazareth, Israel
  • Petah-Tikv, Israel
  • Rechovot, Israel
  • Tel Hashomer, Israel
  • Tel-Aviv, Israel
• Japan
  • Bunkyo, Japan
  • Bunkyo-Ku, Japan
  • Chikushinoshi, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kurashiki, Japan
  • Kurume, Japan
  • Nagoya, Japan
  • Nishinomiya, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Sakura, Japan
  • Sapporo, Japan
  • Sapporo-Shi, Japan
  • Tokyo, Japan
  • Tokyo N/A, Japan
  • Yokkaichi, Japan
• Latvia
  • Balvi, Latvia
  • Daugavpils, Latvia
  • Riga, Latvia
• Lithuania
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Vilnius Lt, Lithuania
• Netherlands
  • Amsterdam, Netherlands
  • Ede Gld, Netherlands
  • Groningen, Netherlands
  • Leiden, Netherlands
  • Nieuwegein, Netherlands
  • Rotterdam, Netherlands
• New Zealand
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • Dunedin, New Zealand
  • Hamilton, New Zealand
  • Hastings, New Zealand
• Poland
  • Bialystok N/A, Poland
  • Bydgoszcz N/A, Poland
  • Czestochowa, Poland
  • Elblag, Poland
  • Gdansk, Poland
  • Gdansk N/A, Poland
  • Krakow, Poland
  • Krakow N/A, Poland
  • Kraków N/A, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Opole N/A, Poland
  • Skierniewice, Poland
  • Sopot, Poland
  • Szczecin, Poland
  • Torun, Poland
  • Warszawa, Poland
  • Warszawa N/A, Poland
• Romania
  • Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Iasi, Romania
  • Targu Mures, Romania
  • Timisoara, Romania
• Russian Federation
  • Moscow, Russian Federation
  • Novosibirsk, Russian Federation
  • Omsk, Russian Federation
  • Saint Petersburg, Russian Federation
  • Smolensk, Russian Federation
  • St Petersburg, Russian Federation
  • St-Petersburg, Russian Federation
  • Yaroslavl, Russian Federation
• Serbia
  • Belgrade, Serbia
  • Beograd, Serbia
  • Nis, Serbia
  • Zemun, Serbia
• Slovakia
  • Bratislava, Slovakia
  • Martin, Slovakia
  • Nitra, Slovakia
  • Nove Mesto Nad Vahom, Slovakia
  • Presov, Slovakia
  • Trnava, Slovakia
• South Africa
  • Cape Town, South Africa
  • Cape Town West Cape, South Africa
  • Durban N/A, South Africa
  • Plumstead West Cape, South Africa
  • Pretoria Gauteng, South Africa
• Sweden
  • Göteborg, Sweden
  • Stockholm, Sweden
• Ukraine
  • Donetsk, Ukraine
  • Ivano, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Poltava, Ukraine
  • Simferopol, Ukraine
  • Vinnitsa, Ukraine
  • Zhaporozhia 69104, Ukraine
• United States
  • Alabama
    • Birmingham, Alabama, United States
  • Arkansas
    • Little Rock, Arkansas, United States
  • California
    • Anaheim, California, United States
    • Merced, California, United States
    • Orange, California, United States
    • Roseville, California, United States
    • San Diego, California, United States
  • Colorado
    • Lakewood, Colorado, United States
    • Littleton, Colorado, United States
  • Connecticut
    • Bristol, Connecticut, United States
  • Delaware
    • Newark, Delaware, United States
  • Florida
    • Boca Raton, Florida, United States
    • Gainesville, Florida, United States
    • Hialeah, Florida, United States
    • Hollywood, Florida, United States
    • Jacksonville, Florida, United States
    • N Miami Beach, Florida, United States
    • Naples, Florida, United States
    • New Port Richey, Florida, United States
    • Port Orange, Florida, United States
    • Tampa, Florida, United States
    • Winter Park, Florida, United States
    • Zephyrhills, Florida, United States
  • Georgia
    • Atlanta, Georgia, United States
    • Decatur, Georgia, United States
    • Savannah, Georgia, United States
    • Snellville, Georgia, United States
  • Illinois
    • Arlington Heights, Illinois, United States
    • Chicago, Illinois, United States
  • Iowa
    • Clive, Iowa, United States
    • Fort Dodge, Iowa, United States
  • Kansas
    • Pratt, Kansas, United States
    • Topeka, Kansas, United States
  • Kentucky
    • Lexington, Kentucky, United States
    • Louisville, Kentucky, United States
  • Louisiana
    • Monroe, Louisiana, United States
  • Maryland
    • Hagerstown, Maryland, United States
    • Hollywood, Maryland, United States
    • Laurel, Maryland, United States
  • Massachusetts
    • Worcester, Massachusetts, United States
  • Michigan
    • Ann Arbor, Michigan, United States
    • Dearborn, Michigan, United States
    • Troy, Michigan, United States
  • Minnesota
    • Plymouth, Minnesota, United States
    • Rochester, Minnesota, United States
  • Mississippi
    • Pascagoula, Mississippi, United States
    • Tupelo, Mississippi, United States
  • Missouri
    • Urbana, Missouri, United States
  • Nevada
    • Las Vegas, Nevada, United States
  • New Hampshire
    • Lebanon, New Hampshire, United States
  • New Jersey
    • Egg Harbor Township, New Jersey, United States
  • New York
    • Great Neck, New York, United States
    • Huntington, New York, United States
    • New York, New York, United States
    • Rochester, New York, United States
  • North Carolina
    • Asheville, North Carolina, United States
    • Boone, North Carolina, United States
    • Charlotte, North Carolina, United States
    • Harrisburg, North Carolina, United States
    • Kinston, North Carolina, United States
    • Morganton, North Carolina, United States
    • New Bern, North Carolina, United States
    • Raleigh, North Carolina, United States
    • Wilmington, North Carolina, United States
    • Winston Salem, North Carolina, United States
  • North Dakota
    • Fargo, North Dakota, United States
  • Ohio
    • Cincinnati, Ohio, United States
    • Cleveland, Ohio, United States
    • Colombus, Ohio, United States
  • Oklahoma
    • Norman, Oklahoma, United States
    • Oklahoma City, Oklahoma, United States
    • Tulsa, Oklahoma, United States
  • Oregon
    • Portland, Oregon, United States
  • Pennsylvania
    • Limerick, Pennsylvania, United States
    • Philadelphia, Pennsylvania, United States
  • South Carolina
    • Charleston, South Carolina, United States
    • Columbia, South Carolina, United States
  • Tennessee
    • Germantown, Tennessee, United States
    • Nashville, Tennessee, United States
  • Texas
    • Austin, Texas, United States
    • Dallas, Texas, United States
    • Galveston, Texas, United States
    • Houston, Texas, United States
  • Utah
    • Logan, Utah, United States
    • Ogden, Utah, United States
  • Vermont
    • Burlington, Vermont, United States
  • Virginia
    • Chesapeake, Virginia, United States
    • Christiansburg, Virginia, United States
    • Fairfax, Virginia, United States
    • Richmond, Virginia, United States
  • Washington
    • Bellevue, Washington, United States
    • Seattle, Washington, United States
    • Spokane, Washington, United States
    • Tacoma, Washington, United States
  • Wisconsin
    • Madison, Wisconsin, United States
    • Milwaukee, Wisconsin, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participants who received all study agent administrations and completed the Week 6 Mayo score evaluation in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
• Participants who completed the Week 0 visit for this maintenance study C0524T18 (NCT00488631) on the same day as the Week 6 visit of the induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)

Exclusion Criteria:

• Participants who increased the dose of their concomitant (given at the same time) UC medications since Week 0 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
• Participants who initiated a concomitant UC medication since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
• Participants who had a partial or total colectomy (surgery to remove part or all of the colon) or an ostomy (surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent) since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
• Participants with signs or symptoms of latent or active granulomatous infection (including TB); a nontuberculous mycobacterial infection or opportunistic infection; or infection with HIV (Human Immunodeficiency Virus), hepatitis B, or hepatitis C
• Participants with signs and symptoms of any malignancy or suggestive of a possible lymphoproliferative disease (disorders characterized by proliferation of lymphoid tissue, general or unspecified)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.	Biological: Placebo; Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).; Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
EXPERIMENTAL: GLM-I-Rsp-Golimumab 50 mg Maintenance; Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.	Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.; Biological: Golimumab 50 mg; Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
EXPERIMENTAL: GLM-I-Rsp-Golimumab 100 mg Maintenance; Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.	Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.; Biological: Golimumab 200 mg; Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
PLACEBO_COMPARATOR: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.	Biological: Placebo; Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).; Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
EXPERIMENTAL: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.	Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
EXPERIMENTAL: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.	Biological: Golimumab 100 mg; Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants in Clinical Response Through Week 54	Clinical response is defined as decrease from induction baseline in Mayo score by greater than or equal to (>=) 30 percent and >= 3, with either decrease from induction baseline in rectal bleeding subscore of >= 1 or rectal bleeding subscore of 0 or 1. Participants who lost clinical response prior to Week 54 were considered not to meet endpoint. Mayo score is sum of 4 subscores (ie, stool frequency, rectal bleeding, endoscopic findings, physician's global assessment); each rated on scale from 0 to 3, with higher scores indicating more severe disease. Total Mayo score value ranges from 0 to 12.	Induction Baseline, Week 0 through Week 54

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Clinical Remission at Both Week 30 and Week 54	Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.	Week 30 and Week 54
Number of Participants With Mucosal Healing at Both Week 30 and Week 54	Mucosal healing is determined from the endoscopy sub-score of the Mayo score. Mucosal healing is defined as an endoscopy sub-score of 0 or 1. Higher score indicates higher severity of disease. Endoscopy sub-score ranges from 0 (normal or inactive disease) to 3 (severe disease; spontaneous bleeding and ulceration). The number of participants with mucosal healing at both the weeks that is Week 30 as well as Week 54 will be reported.	Week 30 and Week 54
Number of Participants With Clinical Remission at Both Week 30 and 54 Among Participants With Clinical Remission at Week 0 of Maintenance Study	Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.	Week 30 and Week 54
Number of Participants With Clinical Remission at Week 54 and Not Receiving Concomitant Corticosteroids Among Participants on Corticosteroids at Week 0 of Maintenance Study	Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12.	Week 54

Collaborators and Investigators

• Sponsor: Janssen Research & Development, LLC
• Collaborators: Merck Sharp & Dohme LLC

Publications and helpful links

General Publications

• Perrig K, Krupka N, Jordi SBU, Rossel JB, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol. 2022 Feb 9;15:17562848221074188. doi: 10.1177/17562848221074188. eCollection 2022.
• Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020 Jan;42(1):157-174.e4. doi: 10.1016/j.clinthera.2019.11.010. Epub 2020 Jan 22.
• Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. J Crohns Colitis. 2019 Sep 27;13(10):1257-1264. doi: 10.1093/ecco-jcc/jjz052.
• Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Aug 29;12(9):1053-1066. doi: 10.1093/ecco-jcc/jjy079.
• Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (ACTUAL): October 1, 2011
• Study Completion (ACTUAL): February 1, 2015

Study Registration Dates

• First Submitted: June 18, 2007
• First Submitted That Met QC Criteria: June 18, 2007
• First Posted (ESTIMATE): June 20, 2007

Study Record Updates

• Last Update Posted (ESTIMATE): April 26, 2016
• Last Update Submitted That Met QC Criteria: March 24, 2016
• Last Verified: March 1, 2016

More Information

Terms related to this study

• Keywords: Golimumab; Colitis, Ulcerative; CNTO 148
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases; Intestinal Diseases; Inflammatory Bowel Diseases; Ulcer; Colitis; Colitis, Ulcerative; Physiological Effects of Drugs; Anti-Inflammatory Agents; Immunosuppressive Agents; Immunologic Factors; Tumor Necrosis Factor Inhibitors; Antibodies, Monoclonal; Golimumab
• Other Study ID Numbers: CR014179; 2006-003399-37 (EUDRACT_NUMBER); C0524T18 (OTHER: Janssen Research & Development, LLC)